Redhill Biopharma Ltd ADR(RDHL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 5:26 PM ET (Korea 9/12 06:26)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 11.09% | Shs Outstand | 6.1M | Perf Week | -9.53% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | -97.79% | Shs Float | 5.4M | Perf Month | 9.31% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 5.19% | Short Float | 0.15% | Perf Quarter | -29.98% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 0.62% | Short Ratio | 0 | Perf Half Y | -26.72% |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.01M | Perf YTD | -37.39% |
| Book/sh | -1.93 | P/C | 1.29 | EPS past 3/5Y | 95.56% 86.32% | ROE | - | 52W High | -76.89% ($2.79) | Perf Year | -59.69% |
| Cash/sh | 0.5 | P/FCF | - | Sales past 3/5Y | -83.27% -66.14% | ROIC | - | 52W Low | 13.14% ($0.57) | Perf 3Y | -96.93% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 94.65% | Gross Margin | - | Volatility(W/M) | 9.87% 11.8% | Perf 5Y | -99.99% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.1 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 0.42 | EPS Q/Q | 102.33% | Profit Margin | - | RSI (14) | 46.56 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.56 | Sales Q/Q | -90.2% | SMA20 | -3.53% ($0.66) | Beta | 4.88 | Target Price | $7.75 |
| Payout | - | Debt/Eq | - | Earnings | 2026/4/27 | SMA50 | -4.36% ($0.67) | Rel Volume | 0.1 | Prev Close | $0.65 |
| Employees | 13 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -30.71% ($0.92) | Avg Volume(3M) | 1.84M | Price | $0.64 |
| IPO | 2013/1/7 | Option/Short | No/Yes | Trades | 365 | Volume | 183,056 | Change | -1.29% |
Company
RDHL is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 RedHill Biopharma () is a specialty pharmaceutical company headquartered in Israel that focuses on gastrointestinal, infectious disease, and oncology therapeutics. Its core revenue driver is Talicia, a treatment for Helicobacter pylori, and the company is working to reduce losses and improve its fundamentals through a co-promotion agreement with Cumberland () in 2025 and progress in its late-stage clinical pipeline.
Over the past 1 year, on the lower side
77% below its 1-year high.
RDHL has weak earning power
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Opinions on the outlook are split
Positive and negative signals are mixed
Tap to view numbers
Holding long would have lost money
Would have changed by -96.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 5.2%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $4M.
RDHL $4M PER -
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is RDHL?
RDHL belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of RDHL?
The market cap of RDHL is approximately $4M, ranking 5,746 within its sector.
What is the 52-week high and low for RDHL?
RDHL has recorded a 52-week high of $2.79 and a low of $0.57.
